NCT06080243View on ClinicalTrials.gov

Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali

PHASE2RecruitingINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

March 19, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

December 31, 2027

Conditions
Healthy Women of Child Bearing Potential
Interventions
BIOLOGICAL

R21/Matrix-M1

10 µg of R21 and 50 µg of Matrix-M1

BIOLOGICAL

Saline and R21/Matrix-M1

Saline and 10 µg of R21 and 50 µg of Matrix-M1

OTHER

Sterile isotonic (0.9%) normal saline

Saline

Trial Locations (1)

Unknown

RECRUITING

Koumantou Study Clinic, Bougouni

All Listed Sponsors
collaborator

Malaria Research and Training Center, Bamako, Mali

OTHER

collaborator

European Vaccine Initiative

OTHER

lead

University of Oxford

OTHER

NCT06080243 - Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali | Biotech Hunter | Biotech Hunter